- Home
- SNCY vs RGNX Comparison
SNCY vs RGNX Comparison
Compare SNCY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- RGNX
- Stock Information
- Founded
- SNCY 1982
- RGNX 2008
- Country
- SNCY United States
- RGNX United States
- Employees
- SNCY N/A
- RGNX N/A
- Industry
- SNCY Air Freight/Delivery Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNCY Consumer Discretionary
- RGNX Health Care
- Exchange
- SNCY Nasdaq
- RGNX Nasdaq
- Market Cap
- SNCY 558.2M
- RGNX 459.1M
- IPO Year
- SNCY 2021
- RGNX 2015
- Fundamental
- Price
- SNCY $14.90
- RGNX $8.47
- Analyst Decision
- SNCY Buy
- RGNX Strong Buy
- Analyst Count
- SNCY 6
- RGNX 12
- Target Price
- SNCY $18.33
- RGNX $36.00
- AVG Volume (30 Days)
- SNCY 694.1K
- RGNX 1.1M
- Earning Date
- SNCY 01-29-2025
- RGNX 11-06-2024
- Dividend Yield
- SNCY N/A
- RGNX N/A
- EPS Growth
- SNCY N/A
- RGNX N/A
- EPS
- SNCY 0.82
- RGNX N/A
- Revenue
- SNCY $1,060,877,000.00
- RGNX $84,327,000.00
- Revenue This Year
- SNCY $4.23
- RGNX $2.34
- Revenue Next Year
- SNCY $7.86
- RGNX $243.67
- P/E Ratio
- SNCY $18.24
- RGNX N/A
- Revenue Growth
- SNCY 2.87
- RGNX N/A
- 52 Week Low
- SNCY $9.22
- RGNX $8.06
- 52 Week High
- SNCY $16.42
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- SNCY 55.26
- RGNX 40.69
- Support Level
- SNCY $14.56
- RGNX $8.06
- Resistance Level
- SNCY $15.44
- RGNX $10.52
- Average True Range (ATR)
- SNCY 0.60
- RGNX 0.73
- MACD
- SNCY 0.01
- RGNX -0.12
- Stochastic Oscillator
- SNCY 54.50
- RGNX 16.67
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.